“Joint pilot study to assess the feasibility of DANA for use by patients with Alzheimer’s disease (AD) and their caregivers, and the reliability of DANA when administered remotely after being administered in a clinical setting. Objectives: (1) assess the in-clinic feasibility of administering a battery of tests via a mobile cognitive performance instrument (i.e., DANA) among AD patient-caregiver dyads; (2) assess the sensitivity of this instrument for detecting mild cognitive impairment (MCI) and dementia; and (3) test the feasibility and reliability of this instrument for assessing in-home cognitive performance. Methods: Participants included 7 dyads of patients diagnosed with mild AD and their informal caregivers. Participants were administered an initial DANA test battery in the clinic, which consisted of 3 simpler cognitive tests (simple reaction time (SRT), procedural reaction time (PRT), and Go/No-Go (GNG)), and 4 more complex cognitive tests (code substitution-learning (CSL), code substitution-recall (CSR), spatial processing (SP) and matching to sample (MTS)). SRT was tested at the beginning of the battery (SRT1) and again at the end of the battery (SRT2). Thereafter, the participants completed at least one DANA test battery per week at home, for a period of 90 days. The at-home test battery only included SRT1, PRT, and GNG. Results: AD patients and multiple caregivers were unable to complete the more complex cognitive tests (CSL, CSR, SP and MTS) in the in-clinic test battery; however, the simpler cognitive tests (SRT1, PRT, GNG and SRT2) were reliability completed by all participants. There were significant differences between the AD patients group and the caregivers group for the in-clinic SRT1 and SRT2 tests. The at-home test results for both AD patients and caregivers were similar to the in-clinic test results for all of the same subtests (SRT1, PRT and GNG). Feasibility of DANA Administration in AD Population: The more complex tests were not appropriate for this population; however, the simpler tests appear to be appropriate and feasible for AD patients and their caregivers in both in-clinic and at-home settings. Validity and Sensitivity of DANA to AD: Results show a reliable transfer of the sensitivity of DANA to cognitive deficits related to AD from in-clinic to at-home settings.”